Abstract
Osteomyelitis of the base of the skull is a rare but life-threatening disease. Although Klebsiella pneumoniae is not a pathogen that is frequently associated with this infection, the clinical course can rapidly progress to meningitis. Here, we describe a case of chronic otitis media, secondary to OXA-48K. pneumoniae, which was complicated by osteomyelitis of the base of the skull and fatal meningitis.
Avoid common mistakes on your manuscript.
1 Introduction
Osteomyelitis of the base of the skull (SBO) was first described in 1775 by Percival Pott as a collection of pus under the pericranium in a patient with forehead trauma and extradural hemorrhage [1]. Malignant otitis externa, paranasal acute and chronic sinusitis and postoperative craniotomy infections are the main risk factors for cranial osteomyelitis [2,3,4,5,6]. Otitis media is not a common cause for SBO [5, 7].
The clinical course of cranial osteomyelitis can be complicated by major neurological events, including cranial nerve palsy, cerebral venous thrombosis, cerebral infarcts, as well as subdural and brain abscesses. Meningitis occurs in 60% of patients with infections in the base of the skull [8]. Pseudomonas aeruginosa is the most frequently implicated pathogen in cranial osteomyelitis [2, 3, 9,10,11,12,13,14,15].
Despite being a rare disease in the era of antibiotics, SBO is a life-threating infection that is difficult to treat, with a 40% mortality rate or long-term neurological sequalae [2, 9, 10, 16, 17].
Here, we describe a fatal case of rapidly progressive SBO secondary to multidrug-resistant Klebsiella pneumoniae (OXA-48).
2 The Case
This was a 65-year-old male patient, known to have liver cirrhosis secondary to hepatitis C infection (Child–Pugh Score B) with a history of spontaneous bacterial peritonitis and portal hypertension. His background history was also significant for ischemic heart disease with previous coronary artery bypass surgery (CABG). He was admitted to hospital electively for trans-jugular intrahepatic portosystemic shunt (TIPS) for the treatment of refractory ascites.
On admission, he gave a history of discharge from the left ear for 4 weeks; this was associated with gait unsteadiness and episodic tinnitus. He denied any history of fever or headache. He used to treat the ear discharge with local antibiotics; this led to a partial reduction in the discharge.
On examination, the patient was fully conscious and oriented to time and place. He was afebrile, with stable vitals and was well saturated on room air. His admission laboratory results were as follows: white blood cells (WBC) 7.65 × 109/l, platelets 255 × 109/l, hemoglobin (Hb) 86 g/dl, alanine transaminase (ALT) 13 international units/l, aspartate transaminase (AST) 31 international units/l, creatinine 195 μmol/l, urea 15 μmol/l, erythrocyte sedimentation rate (ESR) 52 mm/h, and international normalized ratio (INR) 1.08.
The otolaryngology physician evaluated him 1 day after admission and reported a profuse discharge from the left ear, a normal external auditory canal, no tragus, and no mastoid tenderness. He was started on ofloxacin ear drops and a sample of ear discharge was obtained for culture.
His temporal bone imaging, performed after admission, indicated soft tissue in the left auditory canal, middle ear cavity and inner ear, as well as opacification of the left mastoid ear cell with erosive changes of the tegmen tympani and mastoid air cell; these findings were suggestive of chronic otitis media and osteomyelitis.
Gram staining of the ear discharge showed gram-negative bacilli. He was empirically started on piperacillin/tazobactam by the primary team. The ear discharge persisted while on piperacillin/tazobactam. The ear culture grew K. pneumoniae and the OXA-48 gene was detected by an Xpert Carba-R Assay, performed on the GeneXpert Instrument System. This assay is a qualitative in vitro diagnostic test designed for the detection and differentiation of the bla KPC, bla NDM, bla VIM, bla VIM, bla OXA-48 and bla IMP gene sequences associated with carbapenem non-susceptibility. This test is carried out by automated real-time polymerase chain reaction (PCR).
The organism was resistant to all third-generation cephalosporins, piperacillin/tazobactam, trimethoprim/sulfamethoxazole, and meropenem, while imipenem was reported as ‘intermediate’ and gentamicin was ‘susceptible’. The organism was resistant to both tigecycline and colistin. At this time, imipenem and gentamicin. Ceftazidime/avibactam was not available.
The ear discharge continued and the patient began to experience fever, progressive headache, increasing weakness, fatigability, and slight confusion. A non-contrast brain MRI was performed (due to worsening kidney function); the results were highly suggestive of ventriculitis. Ceftazidime/avibactam became available and was started within 5 days of admission. Meropenem was later added for synergistic effect. Lumbar puncture was performed and was suggestive of bacterial meningitis with elevated WBC and low glucose (Table 1). Cerebrospinal fluid (CSF) grew the same OXA-48-producing K. pneumoniae. On day 10 after admission, the patient had a seizure and developed a lower level of consciousness, thus requiring intensive care unit (ICU) admission and intubation. An external ventricular drain was inserted. His clinical condition did not improve; the deteriorated further and died.
3 Discussion
Here, we describe the clinical presentation and rapid progression to fatal meningitis in an immunocompromised patient with SBO, secondary to chronic otitis media. The rapid progression and fatal outcome probably resulted from the nature of the organism isolated (OXA-48K. pneumoniae) and the delay in administrating ceftazidime/avibactam. This clinical scenario should alert physicians that SBO due to OXA-48K. pneumoniae can be the hallmark of fulminant infection with a devastating outcome.
Skull base osteomyelitis (SBO) is the term applied to infections of the temporal, sphenoid, or occipital bones. This condition can be divided into two main groups based on the precipitating etiology: sinorhino-otogenic origin and other origins. The other origins include iatrogenic, post-traumatic, hematologic, and other etiologies. In developed countries, cranial osteomyelitis occurs mostly as postoperative craniotomy-related infections, along with paranasal sinusitis and ear infections (mainly otitis externa); however, direct head injuries are the most frequent cause of cranial osteomyelitis in developing countries.
Otitis media is not a common adult disease, with a reported incidence of 2.7 per 1000 person-years in those above the age of 65 years [18, 19]. Meningitis complicating otitis media is also not frequently encountered in adults. One study estimated the rate at 0.42 per 100,000 per year [20]. In another study, only 3 of 2475 patients with acute otitis media developed meningitis [21]. Cranial involvement of the base of the skull in otitis media occurs through ascending infection from the middle ear, involving the lateral temporal bone and the petrous apex and clivus [16, 22, 23].
An age exceeding 65 years, male sex, and immune compromised state such as diabetes, leukemia, neutropenia, liver cirrhosis, chronic renal failure, malignancies, arteriosclerosis, orbital, oral, or dental infections all predispose patients to extensive infection that spreads to involve the cranial bones and nerves [2, 24,25,26,27,28,29].
Depending on the predisposing site of infection, patients with cranial osteomyelitis may present with aural symptoms, such as otorrhea, otalgia, hearing impairment, headache, and facial pain. Due to the spread of infection, the cranial nerves in the base of the skull, including the oculomotor, trigeminal, abducens, facial, vestibulocochlear, glossopharyngeal, vagus, accessory, and hypoglossal nerves, may be affected to variable degrees. The clinical course may also be complicated by multiple cerebral infarctions, secondary to sinovenous thrombosis or carotid artery involvement.
K. pneumoniae causes a broad spectrum of both community and healthcare related infections, including pneumonia, bloodstream infection, surgical site infections, liver abscess, and meningitis [30,31,32,33]. K. pneumoniae, however, is not a frequent cause of otitis media and SBO, and when it occurs, the clinical course is usually severe [5, 34,35,36,37].
The emergence of carbapenemase-producing K. pneumoniae as a cause of both community- and healthcare-related life-threating infections implicates this organism in ear infections and SBO in immunocompromised hosts; thus, the incidence of this condition will likely increase [38,39,40].
Effective antibiotic therapy is the gold standard of therapeutic interventions for SBO. Antibiotics should be culture-guided when possible. However, broad-spectrum antibiotics are often used because samples for culture are difficult to acquire. Good bone penetration is essential in choosing the correct antibiotic. The emergence of multidrug-resistant (MDR) strains, especially carbapenemase-producing bacteria, may make the therapeutic choices more challenging for both cranial bone osteomyelitis and its complications. The novel cephalosporin/β-lactamase inhibitor combination ceftazidime/avibactam may be the only available therapy for MDR K. pneumoniae infection. However, there are still insufficient data available regarding the CSF penetration of ceftazidime/avibactam [41,42,43,44,45,46,47,48]. In an animal model of meningitis, ceftazidime and avibactam both exhibited a 38% mean CSF penetration [41] with a reduction of bacterial loads to a mean of 5.66 log10 colony-forming units (CFU) over 8 h.
In a human case of carbapenemase-producing K. pneumoniae meningitis, it took 3 days (11 doses) of standard dosing to reach a therapeutic CSF level [42, 49]. In clinical practice, ceftazidime and avibactam are frequently used in combination with other drugs, such as colistin, aminoglycosides and carbapenems [43, 46,47,48]. In our case, and despite the apparent synergism between ceftazidime/avibactam and meropenem, the outcome was not favorable.
Evidence regarding the use of ceftazidime and avibactam for SBO is also very limited. The drug had a curation rate of 78% for the treatment of bone and joint infections in a previous cohort of 15 patients; however, none of these patients had SBO [50]. A few sporadic cases of cervical osteomyelitis have been successfully treated with ceftazidime/avibactam [51].
The duration of antibiotic therapy for SBO is not known, although the early initiation of antibiotics and treatment for at least 3 months is known to reduce post-infection complications [22, 52]. Early surgical debridement may be necessary depending on the extent of the disease for bacterial SBO, but it is more frequently required in cases due to a fungal infection [53, 54]. Other forms of adjuvant therapy, such as hypobaric oxygen have been attempted [22, 55]. Furthermore, meningitis due to SBO also requires prolonged therapy [43,44,45,46,47,48, 56]. The course of our patient was complicated because of the lack of effective antibiotic therapy (ceftazidime/avibactam) early in the treatment course.
4 Conclusion
SBO complicated by OXA-48K. pneumoniae infection, originating from otitis media, can progress quickly to fatal meningitis, especially in immunocompromised patients. Early appropriate antibiotic therapy is crucial.
Availability of Data and Material
Not applicable.
Abbreviations
- ALP:
-
Alkaline Phosphatase
- ALT:
-
Alanine transaminase
- AST:
-
Aspartate transaminase
- CABG:
-
Coronary artery bypass surgery
- CSF:
-
Cerebrospinal fluid
- ESR:
-
erythrocyte sedimentation rate
- Hb:
-
Hemoglobin
- ICU:
-
Intensive care unit
- INR:
-
International normalized ratio
- MDR:
-
Multidrug-resistant
- MRI:
-
Magnetic resonance imaging
- PCR:
-
Polymerase chain reaction
- SBO:
-
Skull base osteomyelitis
- SPECT:
-
Single-photon emission CT
- TIPS:
-
Trans jugular intrahepatic portosystemic shunt
- WBC:
-
White blood cell
References
Pott P. Observations on the nature and consequences of those injuries to which the head is liable from external violence. London: Hawes, Clarke and Collins; 1768.
Prasad KC, Prasad SC, Mouli N, Agarwal S. Osteomyelitis in the head and neck. Acta Otolaryngol. 2007;127(2):194–205. https://doi.org/10.1080/00016480600818054.
Mortazavi MM, Khan MA, Quadri SA, Suriya SS, Fahimdanesh KM, Fard SA, et al. Cranial osteomyelitis: a comprehensive review of modern therapies. World Neurosurg. 2018;111:142–53. https://doi.org/10.1016/j.wneu.2017.12.066.
Bruschini L, Berrettini S, Christina C, Ferranti S, Fabiani S, Cavezza M, et al. Extensive skull base osteomyelitis secondary to malignant otitis externa. J Int Adv Otol. 2019;15(3):463–5. https://doi.org/10.5152/iao.2019.5406.
Low W-K, Lhu H-L. Skull base osteomyelitis from otitis media presenting as the Collet-Sicard syndrome. Case Rep Otolaryngol. 2018;2018:1407417. https://doi.org/10.1155/2018/1407417.
Laurens MB, Becker RM, Johnson JK, Wolf JS, Kotloff KL. MRSA with progression from otitis media and sphenoid sinusitis to clival osteomyelitis, pachymeningitis and abducens nerve palsy in an immunocompetent 10-year-old patient. Int J Pediatr Otorhinolaryngol. 2008;72(7):945–51. https://doi.org/10.1016/j.ijporl.2008.02.025.
Merchant S, Vernick DM. Osteomyelitis of the temporal bone and skull base in diabetes resulting from otitis media. Skull Base Surg. 1992;2(4):207–12. https://doi.org/10.1055/s-2008-1057137.
Das S, Iyadurai R, Gunasekaran K, Karuppusamy R, Mathew Z, Rajadurai E, et al. Clinical characteristics and complications of skull base osteomyelitis: a 12-year study in a teaching hospital in South India. J Family Med Primary Care. 2019;8(3):834–9. https://doi.org/10.4103/jfmpc.jfmpc_62_19.
Balm AJ, Tiwari RM, de Rijcke TB. Osteomyelitis in the head and neck. J Laryngol Otol. 1985;99(10):1059–65. https://doi.org/10.1017/s0022215100098182.
Peltola H, Pääkkönen M. Acute osteomyelitis in children. N Engl J Med. 2014;370(4):352–60. https://doi.org/10.1056/NEJMra1213956.
Nisbet M, Briggs S, Ellis-Pegler R, Thomas M, Holland D. Propionibacterium acnes: an under-appreciated cause of post-neurosurgical infection. J Antimicrob Chemother. 2007;60(5):1097–103. https://doi.org/10.1093/jac/dkm351.
Phillips NI, Robertson IJ. Osteomyelitis of the skull vault from a human bite. Br J Neurosurg. 1997;11(2):168–9. https://doi.org/10.1080/02688699746582.
Larsson A, Engström M, Uusijärvi J, Kihlström L, Lind F, Mathiesen T. Hyperbaric oxygen treatment of postoperative neurosurgical infections. Neurosurgery. 2002;50(2):287–95 (discussion 295-296).
Carfrae MJ, Kesser BW. Malignant otitis externa. Otolaryngol Clin North Am. 2008;41(3):537–49 (viii–ix). https://doi.org/10.1016/j.otc.2008.01.004.
Rubin Grandis J, Branstetter BFT, Yu VL. The changing face of malignant (necrotising) external otitis: clinical, radiological, and anatomic correlations. Lancet Infect Dis. 2004;4(1):34–9. https://doi.org/10.1016/s1473-3099(03)00858-2.
Johnson AK, Batra PS. Central skull base osteomyelitis: an emerging clinical entity. Laryngoscope. 2014;124(5):1083–7. https://doi.org/10.1002/lary.24440.
Ridder GJ, Breunig C, Kaminsky J, Pfeiffer J. Central skull base osteomyelitis: new insights and implications for diagnosis and treatment. Eur Arch Otorhinolaryngol. 2015;272(5):1269–76. https://doi.org/10.1007/s00405-014-3390-y.
Pontefract B, Nevers M, Fleming-Dutra KE, Hersh A, Samore M, Madaras-Kelly K. Diagnosis and antibiotic management of otitis media and otitis externa in United States veterans. Open Forum Infect Dis. 2019;6(11):ofz432. https://doi.org/10.1093/ofid/ofz432.
Rijk MH, Hullegie S, Schilder AGM, Kortekaas MF, Damoiseaux R, Verheij TJM, et al. Incidence and management of acute otitis media in adults: a primary care-based cohort study. Fam Pract. 2021;38(4):448–53. https://doi.org/10.1093/fampra/cmaa150.
Ibrahim SI, Cheang PP, Nunez DA. Incidence of meningitis secondary to suppurative otitis media in adults. J Laryngol Otol. 2010;124(11):1158–61. https://doi.org/10.1017/s0022215110000976.
Kucur C, Özbay İ, Topuz MF, Erdoğan O. Complications of acute otitis media: a single center experience. J Clin Exp Investig. 2017;8(4):120–3.
Khan MA, Quadri SAQ, Kazmi AS, Kwatra V, Ramachandran A, Gustin A, et al. A comprehensive review of skull base osteomyelitis: diagnostic and therapeutic challenges among various presentations. Asian J Neurosurg. 2018;13(4):959–70. https://doi.org/10.4103/ajns.AJNS_90_17.
van Kroonenburgh A, van der Meer WL, Bothof RJP, van Tilburg M, van Tongeren J, Postma AA. Advanced imaging techniques in skull base osteomyelitis due to malignant otitis externa. Curr Radiol Rep. 2018;6(1):3. https://doi.org/10.1007/s40134-018-0263-y.
Slattery WH 3rd, Brackmann DE. Skull base osteomyelitis. Malignant external otitis. Otolaryngol Clin North Am. 1996;29(5):795–806.
Sreepada GS, Kwartler JA. Skull base osteomyelitis secondary to malignant otitis externa. Curr Opin Otolaryngol Head Neck Surg. 2003;11(5):316–23. https://doi.org/10.1097/00020840-200310000-00002.
Rothholtz VS, Lee AD, Shamloo B, Bazargan M, Pan D, Djalilian HR. Skull base osteomyelitis: the effect of comorbid disease on hospitalization. Laryngoscope. 2008;118(11):1917–24. https://doi.org/10.1097/MLG.0b013e31817fae0d.
Sylvester MJ, Sanghvi S, Patel VM, Eloy JA, Ying YM. Malignant otitis externa hospitalizations: analysis of patient characteristics. Laryngoscope. 2017;127(10):2328–36. https://doi.org/10.1002/lary.26401.
Glynn F, Walsh RM. Necrotizing otitis externa: a new trend? Report of 6 atypical cases. Ear Nose Throat J. 2009;88(12):1261–3.
van Duin D, Perez F, Rudin SD, Cober E, Hanrahan J, Ziegler J, et al. Surveillance of carbapenem-resistant Klebsiella pneumoniae: tracking molecular epidemiology and outcomes through a regional network. Antimicrob Agents Chemother. 2014;58(7):4035–41. https://doi.org/10.1128/aac.02636-14.
Yu WL and Chuang YC (2015) Clinical features, diagnosis, and treatment of Klebsiella pneumoniae infection. Calderwood, Up To Date
Yu W-L and Chuang Y-C (2015) Invasive liver abscess syndrome caused by Klebsiella pneumoniae. UpToDate
Chan K-S, Yu W-L, Tsai C-L, Cheng K-C, Hou C-C, Lee M-C, et al. Pyogenic liver abscess caused by Klebsiella pneumoniae: analysis of the clinical characteristics and outcomes of 84 patients. Chin Med J. 2007;120(2):136–9.
Ku YH, Chuang YC, Yu WL. Clinical spectrum and molecular characteristics of Klebsiella pneumoniae causing community-acquired extrahepatic abscess. J Microbiol Immunol Infect. 2008;41(4):311–7.
Yang TH, Kuo ST, Young YH. Necrotizing external otitis in a patient caused by Klebsiella pneumoniae. Eur Arch Otorhinolaryngol. 2006;263(4):344–6. https://doi.org/10.1007/s00405-005-0998-y.
Kanjanawasee D, Chaowanapanja P, Keelawat S, Snidvongs K. Sphenoid sinus cholesteatoma-complications and skull base osteomyelitis: case report and review of literature. Clin Med Insights Case Rep. 2019;12:1179547619835182. https://doi.org/10.1177/1179547619835182.
Muranjan SN, Khadilkar SV, Wagle SC, Jaggi ST. Central skull base osteomyelitis: diagnostic dilemmas and management issues. Indian J Otolaryngol Head Neck Surg. 2016;68(2):149–56. https://doi.org/10.1007/s12070-015-0919-3.
Woo K-N, Roh J-E, Baik S-K, Shin D-H, Park K-S, Park M-G, et al. Central skull base osteomyelitis due to nasopharyngeal Klebsiella infection. J Neurocrit Care. 2020;13(2):119–22.
Anwar S, Acharya S, Thapa S, Rabadi J, Mobarakai N. Carbapenemase producing Klebsiella pneumoniae (KPC) meningitis from chronic otitis media. IDCases. 2020;22:e00963. https://doi.org/10.1016/j.idcr.2020.e00963.
Khatri A, Naeger Murphy N, Wiest P, Osborn M, Garber K, Hecker M, et al. Community-acquired pyelonephritis in pregnancy caused by KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2015;59(8):4375–8. https://doi.org/10.1128/aac.00553-15.
Martin RM, Bachman MA. Colonization, infection, and the accessory genome of Klebsiella pneumoniae. Front Cell Infect Microbiol. 2018;8:4. https://doi.org/10.3389/fcimb.2018.00004.
Cottagnoud P, Merdjan H, Acosta F, Levasseur P, Cottagnoud M, Lowther J et al. Pharmacokinetics of the new β-lactamase inhibitor NXL104 in an experimental rabbit meningitis model: restoration of the bacteriological efficacy of ceftazidime (CAZ) against a class C producing K. pneumoniae
Yasmin M, Hanrahan J, Marshall S, Lodise TP, Chen L, Perez F, et al. Using therapeutic drug monitoring to treat KPC-producing Klebsiella pneumoniae central nervous system infection with ceftazidime/avibactam. Open Forum Infect Dis. 2020;7(9):ofaa349. https://doi.org/10.1093/ofid/ofaa349.
Holyk A, Belden V, Lee JJ, Musick W, Keul R, Britz GW, et al. Ceftazidime/avibactam use for carbapenem-resistant Klebsiella pneumoniae meningitis: a case report. J Antimicrob Chemother. 2018;73(1):254–6. https://doi.org/10.1093/jac/dkx358.
Samuel S, Edwards NJ, Rojas LJ, Rudin SD, Marshall SH, Cicco ID, et al. Ceftazidime-avibactam for the treatment of post-neurosurgical meningitis caused by a Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae. Open Forum Infect Dis. 2016;3(suppl_1):1182. https://doi.org/10.1093/ofid/ofw172.885.
Rodríguez-Núñez O, Ripa M, Morata L, de la Calle C, Cardozo C, Fehér C, et al. Evaluation of ceftazidime/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa. J Glob Antimicrob Resist. 2018;15:136–9. https://doi.org/10.1016/j.jgar.2018.07.010.
Xipell M, Bodro M, Marco F, Losno RA, Cardozo C, Soriano A. Clinical experience with ceftazidime/avibactam in patients with severe infections, including meningitis and lung abscesses, caused by extensively drug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents. 2017;49(2):266–8. https://doi.org/10.1016/j.ijantimicag.2016.11.005.
Gofman N, To K, Whitman M, Garcia-Morales E. Successful treatment of ventriculitis caused by Pseudomonas aeruginosa and carbapenem-resistant Klebsiella pneumoniae with i.v. ceftazidime-avibactam and intrathecal amikacin. Am J Health Syst Pharm. 2018;75(13):953–7. https://doi.org/10.2146/ajhp170632.
Daccò V, Claut L, Piconi S, Castellazzi L, Garbarino F, Teri A, et al. Successful ceftazidime-avibactam treatment of post-surgery Burkholderia multivorans genomovar II bacteremia and brain abscesses in a young lung transplanted woman with cystic fibrosis. Transpl Infect Dis. 2019;21(3):e13082. https://doi.org/10.1111/tid.13082.
Li J, Lovern M, Green ML, Chiu J, Zhou D, Comisar C, et al. Ceftazidime-avibactam population pharmacokinetic modeling and pharmacodynamic target attainment across adult indications and patient subgroups. Clin Transl Sci. 2019;12(2):151–63. https://doi.org/10.1111/cts.12585.
Rempenault C, Pagis V, Noussair L, Berbescu S, Duran C, Bouchand F, et al. Treatment of bone and joint infections by ceftazidime/avibactam and ceftolozane/tazobactam: a cohort study. J Global Antimicrobial Resistance. 2021;25:282–6 (2021/06/01/). https://doi.org/10.1016/j.jgar.2021.04.003.
Meschiari M, Franconi I, Bacca E, Bianco V, Orlando G, Cuomo G, et al. Ceftazidime/avibactam and ceftolozane/tazobactam for the treatment of extensively drug-resistant Pseudomonas aeruginosa post-neurosurgical infections: three cases and a review of the literature. Infection. 2021;49(3):549–53. https://doi.org/10.1007/s15010-020-01539-9.
Prasad SC, Prasad KC, Kumar A, Thada ND, Rao P, Chalasani S. Osteomyelitis of the temporal bone: terminology, diagnosis, and management. J Neurol Surg B Skull Base. 2014;75(5):324–31. https://doi.org/10.1055/s-0034-1372468.
Alva B, Prasad KC, Prasad SC, Pallavi S. Temporal bone osteomyelitis and temporoparietal abscess secondary to malignant otitis externa. J Laryngol Otol. 2009;123(11):1288–91. https://doi.org/10.1017/s0022215109005313.
Hsiao YC, Lee JC, Kang BH, Lin YS. Idiopathic osteomyelitis at the base of the skull. South Med J. 2006;99(10):1121–3. https://doi.org/10.1097/01.smj.0000224745.75981.52.
Amaro CE, Espiney R, Radu L, Guerreiro F. Malignant (necrotizing) externa otitis: the experience of a single hyperbaric centre. Eur Arch Otorhinolaryngol. 2019;276(7):1881–7. https://doi.org/10.1007/s00405-019-05396-7.
Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39(9):1267–84. https://doi.org/10.1086/425368.
Funding
This study did not receive any specific form of funding.
Author information
Authors and Affiliations
Contributions
WB developed the idea, designed the method and wrote the manuscript. JS reviewed and revised the manuscript and updated the references. LL wrote and revised the manuscript.
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare no competing interest.
Ethical Approval and Consent to Participate
Patient consent is not applicable because this is a retrospective case. No particular private information beyond the clinical case is revealed.
Consent for Publication
The authors have consented to publication.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Baharoon, W., Shamou, J. & Layqah, L. A Fatal Case of Meningitis Complicating Chronic Otitis Media and Base of Skull Osteomyelitis due to Carbapenemase (OXA-48)-Producing Klebsiella pneumoniae. Dr. Sulaiman Al Habib Med J 5, 23–28 (2023). https://doi.org/10.1007/s44229-022-00024-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s44229-022-00024-9